Chapter title |
Ex Vivo Expansion of Hematopoietic Stem Cells to Improve Engraftment in Stem Cell Transplantation.
|
---|---|
Chapter number | 19 |
Book title |
Cell Cycle Synchronization
|
Published in |
Methods in molecular biology, January 2017
|
DOI | 10.1007/978-1-4939-6603-5_19 |
Pubmed ID | |
Book ISBNs |
978-1-4939-6602-8, 978-1-4939-6603-5
|
Authors |
Kap-Hyoun Ko, Robert Nordon, Tracey A. O’Brien, Geoff Symonds, Alla Dolnikov, Ko, Kap-Hyoun, Nordon, Robert, O'Brien, Tracey A, Symonds, Geoff, Dolnikov, Alla, O’Brien, Tracey A. |
Editors |
Gaspar Banfalvi |
Abstract |
The efficient use of hematopoietic stem cells (HSC) for transplantation is often limited by the relatively low numbers of HSC collected. The ex vivo expansion of HSC for clinical use is a potentially valuable and safe approach to increase HSC numbers thereby increasing engraftment and reducing the risk of morbidity from infection. Here, we describe a protocol for the robust ex vivo expansion of human CD34(+) HSC isolated from umbilical cord blood. The protocol described can efficiently generate large numbers of HSC. We also describe a flow cytometry-based method using high-resolution division tracking to characterize the kinetics of HSC growth and differentiation. Utilizing the guidelines discussed, it is possible for investigators to use this protocol as presented or to modify it for their specific needs. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 37 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 21% |
Student > Ph. D. Student | 8 | 21% |
Student > Master | 6 | 16% |
Student > Doctoral Student | 2 | 5% |
Other | 2 | 5% |
Other | 2 | 5% |
Unknown | 10 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 11 | 29% |
Agricultural and Biological Sciences | 7 | 18% |
Chemical Engineering | 2 | 5% |
Engineering | 2 | 5% |
Medicine and Dentistry | 2 | 5% |
Other | 4 | 11% |
Unknown | 10 | 26% |